ERBB2 and neoplasm: This peptide-based cancer vaccine was evaluated in a HER2+ breast cancer mouse model, resulting in a promising immune response of CD8+ and CD4+, a significant cytokine secretion of IL-4 and IFN-γ, and a notable reduction in tumor size and increase of survival time [18].